Patents by Inventor Karl Tryggvason

Karl Tryggvason has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7799529
    Abstract: The present invention provides for compositions and methods for detecting susceptibility for basement membrane disease, in particular congenital nephrotic syndromes of the Finnish type. The present invention provides for nucleic acids and protein for use in methods and compositions for the diagnosis of disease and identification of small molecule therapeutics for treatment of such disease, in particular of proteinuria associated with kidney disease.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: September 21, 2010
    Assignee: Athena Diagnostics, Inc.
    Inventors: Karl Tryggvason, Marjo Kestila, Ulla Lenkkeri, Minna Mannikko
  • Publication number: 20100203635
    Abstract: Compositions and processes for culturing human stem cells in vitro in an undifferentiated state are disclosed. In this regard, human embryonic stem cells proliferated and maintained their pluripotency when cultured on plates coated with recombinant laminin-10 (laminin-511).
    Type: Application
    Filed: March 17, 2010
    Publication date: August 12, 2010
    Inventors: Karl Tryggvason, Sergey Rodin, Anna Domogatskaya
  • Publication number: 20080213885
    Abstract: The present disclosure is directed to the development of compositions, such as extracellular matrices, and processes for using the same, for culturing stem cells in vitro in an undifferentiated state. In this regard, it has been discovered that when pluripotent mouse and human embryonic stem cells are cultured on plates coated with recombinant laminin-10 (laminin-511) or laminin-5 (laminin-322), or their functional domains, the embryonic stem cells proliferated and maintained their pluripotency.
    Type: Application
    Filed: January 4, 2008
    Publication date: September 4, 2008
    Inventors: Karl Tryggvason, Anna Domogatskaya, Sergey Rodin
  • Publication number: 20070202111
    Abstract: The present invention provides a methods and compositions for inhibiting tumor growth and/or metastasis involving the administering to a subject with a laminin 5-secreting tumor of an amount effective to inhibit tumor growth and/or metastasis of an antibody that binds to one or more epitopes of the laminin 5 ?2 chain.
    Type: Application
    Filed: August 25, 2006
    Publication date: August 30, 2007
    Inventors: Karl Tryggvason, Sirpa Salo
  • Publication number: 20070077252
    Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.
    Type: Application
    Filed: September 18, 2006
    Publication date: April 5, 2007
    Inventors: Karl Tryggvason, Pekka Kallunki, Charles Pyke
  • Publication number: 20070065447
    Abstract: Novel peptides that specifically bind the ?2 chain of laminin-5 and other ?2-associated proteins; related compositions (e.g., derivatives and variants of such peptides; nucleic acids comprising sequences encoding such peptides; pharmaceutical compositions comprising either of such molecules; etc.); methods of using the same for diagnostic, prophylactic, and therapeutic purposes; and additional new and useful related compositions and methods are provided.
    Type: Application
    Filed: April 28, 2006
    Publication date: March 22, 2007
    Applicants: Novo Nordisk A/S, BioStratum Incorporated
    Inventors: Karl Tryggvason, Ida Mathiasen, Soren Padkaer, Svetlana Tarabykina, Sirpa Salo, Ariel Boutaud
  • Publication number: 20070009952
    Abstract: The present invention provides for compositions and methods for detecting susceptibility for basement membrane disease, in particular congenital nephrotic syndromes of the Finnish type. The present invention provides for nucleic acids and protein for use in methods and compositions for the diagnosis of disease and identification of small molecule therapeutics for treatment of such disease, in particular of proteinuria associated with kidney disease.
    Type: Application
    Filed: September 12, 2006
    Publication date: January 11, 2007
    Inventors: Karl Tryggvason, Marjo Kestila, Ulla Lenkkeri, Minna Mannikko
  • Publication number: 20060216722
    Abstract: The present invention provides compositions comprising various glomerular probe sets and methods for their use.
    Type: Application
    Filed: March 25, 2005
    Publication date: September 28, 2006
    Inventors: Christer Betsholtz, Karl Tryggvason, Minoru Takemoto, Liqun He, Jaakko Patrakkas
  • Patent number: 7105291
    Abstract: The present invention provides for compositions and methods for detecting susceptibility for basement membrane disease, in particular Congenital nephrotic syndromes of the Finnish type. The present invention provides for nucleic acids and protein for use in methods and compositions for the diagnosis of disease and identification of small molecule therapeutics for treatment of such disease, in particular of proteinuria associated with kidney disease.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: September 12, 2006
    Assignee: Biostratum, Inc.
    Inventors: Karl Tryggvason, Marjo Kestila, Ulla Lenkkeri, Minna Mannikko
  • Patent number: 6955924
    Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: October 18, 2005
    Assignee: BioStratum, Inc.
    Inventors: Karl Tryggvason, Pekka Kallunki, Charles Pyke
  • Patent number: 6933273
    Abstract: The present invention provides isolated laminin 10, methods for making recombinant laminin 10, host cells that express recombinant laminin 10, and methods for using the recombinant laminin 10 to accelerate the healing of injuries to vascular tissue, and to promote cell attachment and migration. The present invention also provides nucleic acid sequences encoding full length human laminin ?5 chain, expression vectors and host cells thereof, and isolated full length human laminin ?5 polypeptide chain.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: August 23, 2005
    Inventors: Karl Tryggvason, Masayuki Doi, Jill Thyboll
  • Publication number: 20050048518
    Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.
    Type: Application
    Filed: December 11, 2003
    Publication date: March 3, 2005
    Inventors: Karl Tryggvason, Pekka Kallunki, Charles Pyke
  • Publication number: 20050019332
    Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.
    Type: Application
    Filed: June 17, 2004
    Publication date: January 27, 2005
    Inventors: Karl Tryggvason, Pekka Kallunki, Charles Pyke
  • Publication number: 20040120959
    Abstract: The present invention provides a methods and compositions for inhibiting tumor growth and/or metastasis involving the administering to a subject with a laminin 5-secreting tumor of an amount effective to inhibit tumor growth and/or metastasis of an antibody that binds to one or more epitopes of the laminin 5 &ggr;2 chain.
    Type: Application
    Filed: October 28, 2003
    Publication date: June 24, 2004
    Inventors: Karl Tryggvason, Sirpa Salo
  • Patent number: 6689090
    Abstract: The instant invention provides for apparatus and methods for the efficient administration of pharmaceuticals to target cells, tissues and/or organs, for a variety of functional uses.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: February 10, 2004
    Assignee: Biostratum, Inc.
    Inventors: Karl Tryggvason, Olavi Lukkarinen, Pirkko Heikkilä, Tarja Parpala
  • Patent number: 6638264
    Abstract: The present invention provides methods and devices for the delivery of pharmaceuticals to target tissues in situ, in vivo, ex vivo, or in vitro. In particular, the methods and devices relate to contacting a target tissue with a pharmaceutical in a re-circulating, oxygenated perfusate solution to provide for effective delivery of the pharmaceutical to the target tissue.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: October 28, 2003
    Assignee: Biostratum Incorporation
    Inventors: Karl Tryggvason, Olavi Lukkarinen, Pirkko Heikkilä, Teija Parpala
  • Patent number: 6638907
    Abstract: The present invention provides substantially purified laminin 8, methods for making recombinant laminin 8, cells that express recombinant laminin 8, and methods for using the recombinant laminin 8 to accelerate the healing of injuries to vascular tissue and tissue of mesenchymal origin, and to promote cell attachment and migration.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: October 28, 2003
    Assignee: BioStratum, Inc.
    Inventors: Jarrko Kortesmaa, Karl Tryggvason
  • Patent number: 6576418
    Abstract: The present invention relates to a method for isolating and identifying the nucleotide sequence of the human gene for the type IV collagen &agr;5(IV) chain. The present invention is directed to the determination of the nucleotide sequence of the gene for the &agr;5(IV) collagen chain in individuals by any method known to the art, e.g. cloning from genomic DNA libraries or amplifying gene regions with the polymerase chain reaction (PCR) and studying their physical properties or nucleotide sequences. In addition, the invention is directed to the use of the nucleotide sequences of the &agr;5(IV) gene to amplify or identify the nucleotide sequences of the &agr;5(IV) gene.
    Type: Grant
    Filed: August 7, 1996
    Date of Patent: June 10, 2003
    Assignee: BioStratum, Inc.
    Inventors: Karl Tryggvason, Sirkka L. Hostikka, Jing Zhou
  • Publication number: 20030100529
    Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.
    Type: Application
    Filed: August 26, 2002
    Publication date: May 29, 2003
    Applicant: BioStratum AB
    Inventors: Karl Tryggvason, Pekka Kallunki, Charles Pyke
  • Publication number: 20030044899
    Abstract: The present invention provides isolated laminin 10, methods for making recombinant laminin 10, host cells that express recombinant laminin 10, and methods for using the recombinant laminin 10 to accelerate the healing of injuries to vascular tissue, and to promote cell attachment and migration.
    Type: Application
    Filed: December 21, 2001
    Publication date: March 6, 2003
    Inventors: Karl Tryggvason, Masayuki Doi, Jill Thyboll